Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Forecast to Reach $55.67 Billion by 2030 at 9.3% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Expected To Change Between 2026 And 2030?
The market for asthma and chronic obstructive pulmonary disease (copd) drugs has experienced significant expansion recently. This market is projected to expand from $35.66 billion in 2025 to $39.07 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, this growth has been driven by factors such as increasing smoking prevalence, urban air pollution, developments in hospital-based respiratory care, the uptake of inhaler technology, and an increase in asthma diagnoses.
The asthma and chronic obstructive pulmonary disease (copd) drugs market is projected to experience substantial expansion over the upcoming years. Its valuation is forecast to reach $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This anticipated growth during the projection period stems from factors such as innovations in biologic drugs, an increasingly elderly populace, declining air quality, the advancement of personalized respiratory medicine, and the availability of homecare respiratory solutions. Key developments anticipated within this timeframe involve a rise in the application of combination inhaler treatments, the increasing uptake of long-acting bronchodilators, the broadening of biologic therapies for severe asthma cases, a movement towards managing respiratory conditions at home, and an escalating need for generic inhalation medications.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp
Which Major Factors Are Driving The Expansion Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?
The rising incidence of smoking is projected to spur the growth of the asthma and COPD drugs market moving forward. Smoking refers to the practice of consuming tobacco products by inhaling their smoke, which can lead to severe health problems such as lung cancer and heart disease. The growing prevalence of smoking is primarily fueled by social influence, wherein peer pressure, cultural norms, and social settings encourage individuals to begin and persist in smoking. Asthma and chronic obstructive pulmonary disease (COPD) drugs are instrumental in alleviating the respiratory damage induced by smoking, achieving this by lowering inflammation, relaxing airway muscles, and enhancing airflow, thereby relieving symptoms and boosting lung function. For example, in 2024, the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, published a study on youth smoking trends, revealing a significant increase in smoking rates, which rose from 22.5% of respondents in 2022 to 40.1% in 2024. Hence, the increasing prevalence of smoking is a key driver for the expansion of the asthma and COPD drugs market.
How Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Structured Across Different Segments?
The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations
3) By Patient Group: Adult, Pediatric, Geriatric
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors
Which Trends Are Shaping The Future Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?
Leading companies in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are concentrating on integrating innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers, to augment benefits like preventing severe asthma attacks, improving inflammation control, and supporting better overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which rapidly relaxes airway muscles for symptom relief, with an inhaled corticosteroid, which reduces underlying airway inflammation, thereby enabling dual capabilities of immediate symptom relief alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US, which is a fixed-dose SABA-ICS rescue inhaler engineered to treat asthma symptoms and help prevent sudden severe breathing problems, featuring its dual-component formulation delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while concurrently addressing airway inflammation, consequently lowering the risk of severe asthma exacerbations and enhancing overall asthma control.
Which Major Players Dominate The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?
Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.
Read the full asthma and chronic obstructive pulmonary disease (copd) drugs market report here:
Which Region Currently Holds The Largest Share Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?
North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp
Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company
Anti Asthmatics And Copd Drugs Market Report 2026
Digital Dose Inhalers Market Report 2026
https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report
Inhaled Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
